Univest
Univest
  • Markets

Shree Ganesh Biotech India Q4 FY26 Results: Announced May 14 2026 Agricultural Biotechnology and Bio-Inputs

  • May 15, 2026
  • Posted by: Kashish Aggarwal
  • Category: News
No Comments
Shree Ganesh Biotech India Q4 FY26 Results

Shree Ganesh Biotech India results were announced on May 14, 2026, at the company’s board meeting. Q4 FY26 PAT approximately Rs 1 crore on revenue approximately Rs 10 crore. Biotech and specialty products company. Results filed with BSE on May 14, 2026. Investors tracking the company will find complete financial data, analysis, and FY27 outlook in this article.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Shree Ganesh Biotech India Q4 FY26 Key Financial Highlights
  • Shree Ganesh Biotech India Performance Analysis
  • Shree Ganesh Biotech India FY27 Outlook
  • Frequently Asked Questions on Shree Ganesh Biotech India Q4 FY26 Results
    • What is Shree Ganesh Biotech India Q4 FY26 PAT?
    • When did Shree Ganesh Biotech India announce Q4 FY26 results?
    • What is the FY27 outlook for Shree Ganesh Biotech India?
    • Where can I track Shree Ganesh Biotech India Q4 FY26 live data?

Shree Ganesh Biotech India Q4 FY26 Key Financial Highlights

Metric Q4 FY26 Comparison
PAT (Net Profit) Rs 1 crore Q4 FY26
Revenue from Operations Rs 10 crore Q4 FY26
Ticker SHREEGBIO Sector: Agricultural Biotechnology and Bio-Inputs

Screen the best stocks on the Univest Screener.

Shree Ganesh Biotech India Performance Analysis

The company results reflect the company’s operational performance during the January to March 2026 quarter. the company results announced May 14, 2026. The company develops and manufactures biological products for agriculture including biofertilisers, biostimulants, and bio-pesticides Investors and analysts monitoring the company results will focus on FY27 revenue guidance, margin trajectory, and management commentary on business outlook.

The company performance positions the company for FY27. Track the company analyst ratings and live stock price on the Univest Screener for real-time investment insights.

Shree Ganesh Biotech India FY27 Outlook

Post Shree, investor focus for FY27 will be on revenue growth momentum, margin expansion, new order wins, and sector-specific tailwinds in the Agricultural Biotechnology and Bio-Inputs space. The Shree results demonstrate the company’s execution capabilities. Track Shree updates on the Univest Screener for analyst views and FY27 earnings estimates.

Download the Univest iOS App or the Univest Android App to track live price and Q4 FY26 earnings updates.

Frequently Asked Questions on Shree Ganesh Biotech India Q4 FY26 Results

What is Shree Ganesh Biotech India Q4 FY26 PAT?

Ans. Shree Ganesh Biotech India Q4 FY26 PAT of Rs 1 crore (results declared May 14, 2026). Q4 FY26 PAT approximately Rs 1 crore on revenue approximately Rs 10 crore. Biotech and specialty products company. Results filed with BSE on May 14, 2.

When did Shree Ganesh Biotech India announce Q4 FY26 results?

Ans. the company results were announced on May 14, 2026, at the company’s board meeting and filed with BSE and NSE.

What is the FY27 outlook for Shree Ganesh Biotech India?

Ans. Post the company results, investors will track FY27 guidance and growth strategies in the Agricultural Biotechnology and Bio-Inputs sector. Track live updates on the Univest Screener.

Where can I track Shree Ganesh Biotech India Q4 FY26 live data?

Ans. Track the company live stock price, analyst ratings, and earnings updates on the Univest Screener for real-time investment data.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered advisor before making any investment decision.



Author: Kashish Aggarwal
Kashish Aggarwal is a Financial Content Writer at Univest, covering Indian equity markets with a focus on share price target frameworks, technical analysis education, and sector deep-dives. Her published work spans bull-case/bear-case share price analysis, event-driven stock reactions, and beginner-friendly educational guides. Her articles blend fundamental analysis (analyst consensus targets, P/E, loan book quality, margin dynamics) with technical analysis (moving averages, 200-DMA, support/resistance levels) — giving retail investors a complete framework before any position. All articles are reviewed by Univest's in-house equity research team, led by Ankit Jaiswal, Senior Equity Research Analyst, to meet SEBI editorial standards. Coverage Areas • Share price targets — REC Ltd, Adani Green Energy (bull/bear case frameworks) • Event-driven analysis — Redington (US tariff impact), Star Cement (technical breakdown) • Technical analysis education — Direct Market Access, 200-DMA, indicator interpretation • Thematic listicles — Highest Dividend Paying Stocks, Real Estate Penny Stocks, Intraday Picks • Sector coverage — IT distribution, renewable energy, infrastructure finance, cement, real estate

Leave a Reply Cancel reply